| 参考文献 | 1) 日本食道学会編 : 食道癌診断・治療ガイドライン2007年4月版, 金原出版, 東京 (2007) pp 10-13.
2) 日本食道学会編 : 食道癌診断・治療ガイドライン2007年4月版, 金原出版, 東京 (2007) pp 61-65.
3) Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, Bedenne L, Namer M, De Besi P, Gay F, Collette L and Sahmoud T : Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer (1997) 33, 1216-1620.
4) 室 圭 : 進行および切除後再発食道癌に対するNedaplatin+ 5 -FU併用療法の第II相臨床試験―JCOG9905―. 癌の臨床 (2004) 50, 269-275.
5) Muro K, Hamaguchi T, Ohtsu A, et al. : A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol (2004) 15, 955-959.
6) 日本胃癌学会編 : 胃癌治療ガイドライン―医師用第2版, 金原出版, 東京 (2004) pp 8-9.
7) Koizumi W, Kurihara M, Nakano S and Hasegawa K : Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology (2000) 58, 191-197.
8) Yamada Y, Shirao K, Ohtsu A, et al. : Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol (2001) 12, 1133-1137.
9) Fujitani K, Narahara H, Takiuchi H, Tsujinaka T, Satomi E, Gotoh M, Hirao M, Furukawa H and Taguchi T : Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer. Oncology (2005) 69, 414-420.
10) Yamao T, Shimada Y, Shirao K, Ohtsu A, Ikeda N, Hyodo I, Saito H, Iwase H, Tsuji Y, Tamura T, Yamamoto S and Yoshida S : Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites : a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Trial. Jpn J Clin Oncol (2004) 34, 316-322.
11) 大腸癌研究会編 : 大腸癌治療ガイドライン2005年版, 金原出版, 東京 (2005).
12) Andre T, Bensmaine MA and Louvert C : Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leukovorin and fluorouracil regimen. J Clin Oncol (1999) 17, 3560-3568.
13) de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F and Bonetti A : Leucovorin and fluoouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol (2000) 18, 2938-2947.
14) Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F : Bevacizumab plus irinotecan, fluorouracil, and leukovorin for metastatic colorectal cancer. N Engl J Med (2004) 350, 2335-2342.
15) 坂口孝作, 小林功幸, 白鳥康史 : 肝細胞癌 : 消化器病診療, 財団法人日本消化器病学会編, 医学書院, 東京 (2004) pp 200-203.
16) 科学的根拠に基づく肝癌診療ガイドライン作成に関する研究班編 : 科学的根拠に基づく肝癌診療ガイドライン2005年版, 金原出版, 東京 (2005).
17) Nouso K, Matsumoto E, Kobayashi Y, Nakamura SI, Tanaka H, Osawa T, Ikeda H, Araki Y, Sakaguchi K and Shiratori Y : Risk factors for local and distant recurrence of hepatocellular carcinomas after local ablation therapies. J Gastroenterol and Hepatol (2007) 27, (in press).
18) 工藤正俊 : 第17回全国原発性肝癌追跡調査報告 (2002-2003) : 肝臓, 日本肝臓学会, 東京 (2007) pp 117-140.
19) Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K and Sata M : Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer (2002) 95, 588-595.
20) Obi S, Yoshida H, Toune R, Unuma T, Kanda M, Sato S, Tateishi R, Teratani T, Shiina S and Omata M : Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer (2006) 106, 1990-1997.
21) Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and Von Hoff DD : J Clin Oncol (1997) 15, 2403-2413.
22) Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saito S, Saito H and Tsuyuguchi T : Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol (2006) 57, 647-653. |
|---|
